Video

Dr. Shuo Ma on Non-Chemotherapy Regimens for Hematologic Malignancies

Shuo Ma, MD, PhD, assistant professor at Northwestern University in the Robert H. Lurie Comprehensive Cancer Center discusses advances in non-chemotherapy regimens for patients with hematologic malignancies.

Shuo Ma, MD, PhD, assistant professor at Northwestern University in the Robert H. Lurie Comprehensive Cancer Center, discusses advances in non-chemotherapy regimens for patients with hematologic malignancies.

Rituximab in combination with bortezomib and rituximab in combination with lenalidomide have shown success for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma . Both combinations provide a fairly high response rate in both the frontline setting and the relapse setting, says Ma.

B-cell receptor pathway inhibitors including ibrutinib and idelalisib also offer exciting benefits. Both have shown significant activity across many different forms of b-cell malignancies.

<<<

View more from the 2015 Congress on Hematologic Malignancies

Related Videos
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School